Pacira BioSciences (PCRX) to Release Earnings on Thursday

Pacira BioSciences (NASDAQ:PCRX) is projected to post its quarterly earnings results after the market closes on Thursday, February 27th. Analysts expect Pacira BioSciences to post earnings of $0.78 per share and revenue of $185.38 million for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Pacira BioSciences Stock Performance

PCRX opened at $25.10 on Wednesday. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51. The business’s 50 day moving average is $22.71 and its 200-day moving average is $18.31. The stock has a market cap of $1.16 billion, a PE ratio of -12.36 and a beta of 0.80. Pacira BioSciences has a twelve month low of $11.16 and a twelve month high of $31.67.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on PCRX shares. Barclays cut their target price on Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating on the stock in a research note on Tuesday, November 12th. HC Wainwright restated a “buy” rating and set a $39.00 price objective on shares of Pacira BioSciences in a research note on Wednesday, December 4th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $18.00 target price on shares of Pacira BioSciences in a research report on Tuesday, January 14th. Needham & Company LLC raised their target price on shares of Pacira BioSciences from $22.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, January 13th. Finally, Truist Financial raised shares of Pacira BioSciences from a “sell” rating to a “hold” rating and upped their price target for the stock from $8.00 to $25.00 in a research note on Thursday, January 30th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, Pacira BioSciences currently has an average rating of “Hold” and a consensus target price of $22.78.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.